Hepatocellular Cancer, Cholangiocarcinoma, and Metastatic Tumors of the Liver

This issue of the Surgical Oncology Clinics of North America discusses hepatocellular cancer, cholangiocarcinoma, and metastatic tumors of the liver. The guest editor is Lawrence D. Wagman, MD, Executive Medical Director of the Center for Cancer Prevention and Treatment at St. Joseph’s Hospital, Orange, California. Dr Wagman completed his general surgery residency at the Medical College of Virginia and also a fellowship at the National Institutes of Health at the National Cancer Institute Surgery Branch. He is an outstanding surgical oncologist with experience in liver, bile duct, and pancreatic surgery. Dr Wagman is an advocate for clinical trials and has spent his entire career developing national protocols and accruing patients to National Cancer Institute clinical trials.

One would think that taking on hepatocellular cancer, cholangiocarcinoma, and metastatic tumors of the liver would be too much information to put into eleven articles. However, Dr Wagman and his colleagues have made an outstanding effort in describing these cancer entities. Dr Pawlik and his colleagues from Johns Hopkins have an excellent discussion on the epidemiology of hepatocellular carcinoma. David Linehan, MD, Chief of the Section of Hepatobiliary-Pancreatic and Gastrointestinal Surgery at Washington University and the Siteman Cancer Center in St. Louis, has an excellent article on imaging approaches to hepatocellular carcinoma, cholangiocarcinoma, and liver metastasis from colorectal cancer. Other articles deal with complications following hepatic resection and hepatic artery infusion chemotherapy for liver malignancy, among other topics.

I’d like to take this opportunity to thank Dr Wagman and his colleagues for this outstanding issue of the Surgical Oncology Clinics of North America . I encourage our readers to share this information with all of their trainees.

Only gold members can continue reading. Log In or Register to continue